1. < Home

idiopathic pulmonary fibrosis

Real-world evidence on hospitalization, infection, and vascular outcomes among interstitial lung disease subtypes

Chao WC, Liao SY. Real-world evidence on hospitalization, infection, and vascular outcomes among interstitial lung disease subtypes. Respir Med Res. 2026 Apr 15;89:101278. doi: 10.1016/j.resmer.2026.101278.[...]

By afschroeder • May 3, 2026
Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis

Kim GHJ, Woodhead FA, Nair D, Bao H, Lazarus HM, Conoscenti CS, Goldin JG. Improved quality of life, reduced quantitative lung fibrosis in a trial[...]

By afschroeder • March 23, 2026
Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension

Piccari L, Allwood B, Antoniou K, Chung JH, Hassoun PM, Nikkho SM, Saggar R, Shlobin OA, Vitulo P, Nathan SD, Wort SJ. Pathogenesis, clinical features,[...]

By sjmartinez • April 8, 2023